Optimal Multimodal Analgesia in Abdominal Hysterectomy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Hvidovre University Hospital.
Recruitment status was  Not yet recruiting
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
First received: September 14, 2005
Last updated: November 6, 2007
Last verified: September 2005
The purpose of this study is to test the current standard of care (SOC) treatment for abdominal hysterectomy with a group receiving SOC minus epidural analgesia plus additional perioperative analgesics in terms of postoperative abilities, postoperative nausea and vomiting (PONV), pain and discharge time from the PACU (post-anaesthesia care unit).

Condition Intervention Phase
Planned Abdominal Hysterectomy
Drug: Gabapentin
Drug: Lidocaine
Drug: S-ketamine
Procedure: Epidural analgesia
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • Postoperative abilities over time
  • Discharge time from PACU according to fixed criteria
  • Consumption of analgesics and antiemetics in the PACU

Secondary Outcome Measures:
  • Degree of nursing requirements at the PACU
  • General tolerability of the regimes
  • Threshold for sensory perception and pain using the Pain Matcher device, pre- and postoperatively

Estimated Enrollment: 60
Study Start Date: October 2005
Detailed Description:

Aim of the study: to compare postoperative complaints (PONV, pain, etc) and PACU discharge time between two groups, for patients admitted for planned abdominal hysterectomy with or without BSO:

  • A: standard of care (SOC) receiving paracetamol, celecoxib, epidural analgesia, dexamethasone, ondansetron and droperidol, and general anaesthesia with propofol, remifentanil and cisatracurium
  • B: SOC with sham epidural analgesia, preoperative gabapentin, intraoperative lidocaine, s-ketamine and sufentanil

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Planned abdominal hysterectomy with or without BSO
  • Age above 18 years
  • Written informed consent
  • American Society of Anesthesiologists (ASA) class I-III

Exclusion Criteria:

  • Planned vaginal or laparoscopic hysterectomy
  • Hysterectomy as part of other surgery
  • Allergy to part of the treatment regimen
  • Previous reactions to opioids (nausea, cognition)
  • Previous inability to place correct epidural catheter
  • Severe state anxiety according to the OCAP or STAI
  • ASA class IV
  • Dependency on alcohol, opioids or central stimulants
  • Chronic pain condition
  • Hemorrhagic diathesis
  • Participation in another study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209872

Contact: Kenneth Jensen, M.D. +45 36 32 62 90 kenneth.jensen@hh.hosp.dk

Dept. of Anaesthesia, Hvidovre Hospital Not yet recruiting
Copenhagen, Hvidovre, Denmark, 2650
Contact: Kenneth Jensen, M.D.    +45 36 32 62 90    kenneth.jensen@hh.hosp.dk   
Principal Investigator: Kenneth Jensen, M.D.         
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Kenneth Jensen, M.D. Dept. of Anaesthesia, Acute Pain Service, Hvidovre Hospital, Copenhagen, Denmark
Study Chair: Claus Lund, Dr. Med. Sci. Dept. of Anaesthesia, Hvidovre Hospital, Copenhagen, Denmark
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00209872     History of Changes
Other Study ID Numbers: OMA-AH01  eudraCT # 2005-003595-38 
Study First Received: September 14, 2005
Last Updated: November 6, 2007
Health Authority: Denmark: Danish Medicines Agency

ClinicalTrials.gov processed this record on May 04, 2016